Cargando…
Can tumor mutational burden determine the most effective treatment for lung cancer patients?
[Image: see text]
Autores principales: | Wang, Shixiang, He, Zaoke, Wang, Xuan, Li, Huimin, Wu, Tao, Sun, Xiaoqin, Wu, Kai, Liu, Xue-Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978725/ https://www.ncbi.nlm.nih.gov/pubmed/31983929 http://dx.doi.org/10.2217/lmt-2019-0013 |
Ejemplares similares
-
Pan-cancer noncoding genomic analysis identifies functional CDC20 promoter mutation hotspots
por: He, Zaoke, et al.
Publicado: (2021) -
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
por: Wang, Shixiang, et al.
Publicado: (2019) -
Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes
por: Wang, Shixiang, et al.
Publicado: (2021) -
APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
por: Wang, Shixiang, et al.
Publicado: (2018) -
Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis
por: Zhao, Xiangyu, et al.
Publicado: (2022)